Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

RxSight Q1 2024 Adj EPS $(0.12) Beats $(0.27) Estimate, Sales $29.512M Beat $27.559M Estimate

Author: Benzinga Newsdesk | May 06, 2024 04:34pm
RxSight (NASDAQ:RXST) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.27) by 55.56 percent. This is a 61.29 percent increase over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $29.512 million which beat the analyst consensus estimate of $27.559 million by 7.09 percent. This is a 68.75 percent increase over sales of $17.489 million the same period last year.

Posted In: RXST


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist